MAP3K1 and glioma: Selumetinib, a highly specific inhibitor of mitogen activated protein kinase 1 and 2, was mainly used in treatments of neurofibromas related to neurofibromatosis type 1, pediatric low-grade gliomas, non-small cell lung cancer, and melanoma (103).